The GNA11 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the GNA11 gene in HeLa cells. This polyclonal knockout model provides a robust loss-of-function system for investigating G protein subunit alpha 11 (G??11)-dependent signaling without the constraints of clonal selection, maintaining genetic heterogeneity while abolishing functional G??11 expression. Ideal for advanced functional genomics studies, the product enables researchers to dissect G??11-mediated pathways in a well-characterized epithelial carcinoma background.
HeLa cells, derived from an HPV18-positive human cervical adenocarcinoma, are an immortalized epithelial cell line widely employed in biomedical research. Their robust proliferation, ease of genetic manipulation, and well-documented signaling networks make them an exemplary host for studying oncogenic and GPCR-related pathways. The epithelial origin is particularly relevant for investigating G??11 function in cell adhesion, migration, and polarity, processes frequently dysregulated in cancer. This background supports detailed mechanistic analyses and translational research.
GNA11 encodes the alpha subunit of the heterotrimeric G protein G11, which couples a diverse array of G protein-coupled receptors (GPCRs), including the calcium-sensing receptor, endothelin receptors, and angiotensin II receptor, to phospholipase C beta (PLC??). Upon receptor activation, G??11 stimulates PLC?? to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), triggering intracellular calcium mobilization and protein kinase C (PKC) activation. These events propagate signaling through the MAPK/ERK cascade (Ras-Raf-MEK-ERK), PI3K-Akt pathway, and RhoA-mediated cytoskeletal rearrangements. G??11 also interacts with G?¦? subunits, GPCR kinases (GRK2), arrestins, and RhoGEFs such as p63RhoGEF and Trio, linking GPCR activation to transcriptional regulation via YAP/TAZ. Activating mutations (Q209L/R183C) are oncogenic drivers in uveal melanoma, highlighting the gene’s critical role in growth control.
In the HeLa context, GNA11 knockout eliminates G??11-mediated signaling, providing a clean background to study GPCR-directed calcium flux, MAPK/ERK activation, and YAP/TAZ nuclear translocation. This model enables discrimination between G??11-dependent and independent pathways, particularly for receptors that may couple to multiple G protein families. HeLa cells express key components such as RAS, RAF1, MEK1/2, and ERK1/2, making them suitable for biochemical reconstitution experiments. The knockout population is especially valuable for uveal melanoma research, allowing comparison of wild-type and mutant G??11 functions in a non-melanocytic system.
Applications include dissecting GPCR signaling cascades, validating downstream targets, and screening small molecules that modulate G??11 activity. Representative assays involve western blotting for phospho-ERK and phospho-Akt, calcium flux measurements using fluorescent indicators, IP1 accumulation assays, RT-qPCR for gene expression profiling, and cell proliferation or migration studies. The polyclonal cells are also amenable to immunofluorescence for YAP/TAZ localization and tumor xenograft models to assess in vivo growth. For further information, please contact Ascent Research.
